CRDF — Cardiff Oncology Share News
0.000.00%
Last trade - 00:00- $70.58m
- $34.93m
- $0.59m
Cardiff Oncology Inc reports results for the quarter ended in September - Earnings Summary
Cardiff Oncology Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Biogen, Generac Holdings, Luminar
U.S. STOCKS ON THE MOVE-Akouos, Core & Main, Revance Therapeutics
U.S. STOCKS ON THE MOVE-Planet Labs, Catalyst Pharma, Akero
Piper cuts Cardiff's PT on shift in focus from prostate cancer therapy
Cardiff Oncology falls after backing off from prostrate cancer treatment study
Brief: Cardiff Oncology Announces Plans For A Randomized Trial In Metastatic Colorectal Cancer (mCRC), Durability Of Responses In Ongoing Phase 1b/2 Trial In mCRC And Additional Business Updates
Brief: Cardiff Oncology To Host Webcast And Conference Call On September 12, 2022
Brief: Cardiff Oncology Inc - QTRLY Loss Per Share $0.24
Cardiff Oncology Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cardiff Oncology Reports First Quarter 2022 Results And Provides Business Updates
Cardiff Oncology Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Cardiff Oncology Inc Files For Mixed Shelf Of Up To $250 Million – SEC Filing
Cardiff Oncology Inc reports results for the quarter ended in December - Earnings Summary
Cardiff Oncology Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Cardiff Oncology Announces New Data From Lead Clinical Program In Kras-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate And Progression Free Survival
Brief: Cardiff Oncology Appoints Tod Smeal As Chief Scientific Officer And Charles Monahan As Senior Vice President, Regulatory Affairs
U.S. RESEARCH ROUNDUP-Elastic, Prometheus Biosciences, Stitch Fix